After next steps are completed , another bracket valuation will...

After next steps are completed , another bracket valuation will come...in Aug..

next steps as per E&P
■ Payer negotiations are ongoing with the list price originally discussed under an NDA, but BOT are moving towards publishing this
number to the payer compendium. The aim is for a favourable net price after accounting for managed care and patient rebates,
copays, pharmacy setup, logistics etc. We assume this net price at launch will be ~$490, with an ~35% gross to net.
■ Launch Preparation is underway with payer negotiations with account managers, clinician meetings, sales staff interviews underway,
marketing preparation and utilisation of crossix data with partners to support target segmentation.
■ The messaging for BOT's Patient Experience Program is currently being finessed to make "alpha" patients within the International
Hyperhidrosis Society database aware of the opportunity.
■ Further detail around the engagement with payers on pricing, as well as feedback on the progress on the Patient Experience
Program is expected at a market update in mid-August.